Landos Biopharma Inc

NASDAQ:LABP   3:59:46 PM EDT
0.70
+0.01 (+1.20%)
Earnings Announcements

Landos Biopharma Reports Fourth Quarter And Full Year 2021 Results

Published: 03/24/2022 21:05 GMT
Landos Biopharma Inc (LABP) - Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update.
Landos Biopharma Inc - on Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later This Year.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.33

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.28

More details on our Analysts Page.